You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 138 No. 4, April 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Skin Cancer
 •Dermatology
 •Dermatologic Disorders
 •Neoplasms
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?


Improved Differentiation of Benign and Malignant Lymphadenopathy in Patients With Cutaneous Melanoma by Contrast-Enhanced Color Doppler Sonography

Monika-Hildegard Schmid-Wendtner, MD; Karin Partscht, MD; Hans Christian Korting, MD; Matthias Volkenandt, MD

Arch Dermatol. 2002;138:491-497.

Objective  To evaluate whether administration of a D-galactose–based signal enhancer is useful in color Doppler sonography (CDS) for better detection of vascularity patterns, which may help to differentiate malignant from benign lymph nodes in patients with cutaneous melanomas.

Design  Comparison of B-mode sonography, native CDS, and signal-enhanced CDS.

Setting  Department of Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany.

Patients  Twenty examinations in 19 patients (median age, 60 years; 10 men) who presented with echo-poor structures suggestive of lymphadenopathy in B-mode sonography during follow-up for cutaneous melanomas.

Interventions  Histopathologic and follow-up examinations; documentation by color prints.

Main Outcome Measures  Frequency of detection and description of different lymph node vascularity patterns in signal-enhanced CDS.

Results  Signal-enhanced CDS revealed additional information about vascularization of lymph node metastases, reactive lymph nodes, hematomas, and seromas, which was helpful for the differential diagnosis in 15 of 20 examinations. For lymph node metastases, signal enhancement facilitated the detection of accessory peripheral vessels in most investigations. Concerning reactive lymph nodes, hilar vessels in part with branching to the lymph node periphery could be identified only after application of the contrast enhancer in most patients. Quantitative variables could not be measured in all cases and did not help to differentiate between malignant and reactive lymph nodes.

Conclusions  Administration of a D-galactose–based signal enhancer for CDS in patients with cutaneous melanomas can help to differentiate malignant from reactive lymph nodes, hematomas, or seromas. However, these promising results require confirmation in a prospective multicenter study.


From the Department of Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2002;138(4):553-554.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ultrasonography Using Simple Diagnostic Criteria vs Palpation for the Detection of Regional Lymph Node Metastases of Melanoma
Saiag et al.
Arch Dermatol 2005;141:183-189.
ABSTRACT | FULL TEXT  

Ultrasound Scanning in Dermatology
Schmid-Wendtner and Burgdorf
Arch Dermatol 2005;141:217-224.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.